Pharmabiz3h
HuidaGene Therapeutics gets US FDA clearance for CRISPR/Cas13 RNA-editing HG202 for macular degeneration
HuidaGene Therapeutics (HuidaGene), a global clinical-stage biotechnology company developing genome medicines, announced that the US FDA has cleared its HG202 investigational new drug (IND) ...
Pharmabiz10h
MannKind completes phase 1 trial of nintedanib DPI for pulmonary fibrotic diseases
MannKind Corporation, a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced ...
Pharmabiz10h
Memo Therapeutics appoints Frits van Alphen, MD as chief development officer
Memo Therapeutics AG (MTx), a late-stage biotech company translating unique immune responses into superior medicines to treat ...
Pharmabiz13h
Health groups and patients calls for government interference to make rare disease drugs affordable
Health groups and patients calls for government interference to make rare disease drugs affordable: Our Bureau, New Delhi Tuesday, November 5, 2024, 18:10 Hrs [IST] Health groups ...
Pharmabiz13h
Diadem presents new findings on early Alzheimer’s disease detection using p53-specific antibody at CTAD 2024
Diadem presents new findings on early Alzheimer’s disease detection using p53-specific antibody at CTAD 2024: Milano, Italy Tuesday, November 5, 2024, 18:00 Hrs [IST] Diadem SpA ...
Pharmabiz14h
Epredia’s SlideMate Laser slide printer receives innovative technology designation from Vizient
Epredia’s SlideMate Laser slide printer receives innovative technology designation from Vizient: Portsmouth, New Hampshire Tuesday, November 5, 2024, 17:00 Hrs [IST] Epredia, a ...
Pharmabiz15h
Healthcare payments company QubeHealth raises pre series A from Unicorn India Ventures and CanBank VC
Healthcare payments company QubeHealth raises pre series A from Unicorn India Ventures and CanBank VC: Our Bureau, Bengaluru Tuesday, November 5, 2024, 16:30 Hrs [IST] Deep-tech f ...
Pharmabiz15h
Gland Pharma in Q2FY25 reports Rs. 1,405.8 crore revenue and profit dip by 16% at Rs.163.5 crore
Gland Pharma in Q2FY25 reports Rs. 1,405.8 crore revenue and profit dip by 16% at Rs.163.5 crore: Our Bureau, Bengaluru Tuesday, November 5, 2024, 16:15 Hrs [IST] Gland Pharma, a ...
Pharmabiz16h
Novo Nordisk announces positive results from phase 3 ESSENCE trial of semaglutide 2.4 mg to treat adults with MASH and liver fibrosis
Novo Nordisk, a leading global healthcare company, announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with ...
Pharmabiz16h
Prokarium expands IP portfolio with two new US patents strengthening its position in bladder cancer
Prokarium expands IP portfolio with two new US patents strengthening its position in bladder cancer: London, UK Tuesday, November 5, 2024, 15:00 Hrs [IST] Prokarium, a biopharmace ...
Pharmabiz17h
Oak Hill Bio, Chiesi announce first European patient enrolled in phase 2b study of OHB-607 for prevention of BPD in premature infants
Oak Hill Bio, Chiesi announce first European patient enrolled in phase 2b study of OHB-607 for prevention of BPD in premature infants: Parma, Italy Tuesday, November 5, 2024, 14:0 ...
Pharmabiz18h
PURE Bioscience enters multi-year distribution agreement with Quip Labs
PURE Bioscience enters multi-year distribution agreement with Quip Labs: El Cajon, California Tuesday, November 5, 2024, 13:00 Hrs [IST] PURE Bioscience, Inc., creator of the pate ...